<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00328523</url>
  </required_header>
  <id_info>
    <org_study_id>0653-060</org_study_id>
    <secondary_id>2006_024</secondary_id>
    <nct_id>NCT00328523</nct_id>
  </id_info>
  <brief_title>TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)</brief_title>
  <official_title>Ezetimibe Together With Any Statin Cholesterol Enhancement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      In patients with primary hypercholesterolemia treated with a statin and with ldl-c above the
      recommended target goal (esc 2003 recommendations ldl&gt;=1.15 g/l) to compare the efficacy and
      the safety of ezetrol added to ongoing statin and non drug therapeutic intervention (patient
      motivation on diet or physical activities or both).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients attaining the ldl cholesterol target goal based on the lipids result at the end of the study (3 months).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment with ezetimibe 10 mg/day will be well tolerated and no difference in tolerance will be shown between the 3 treatment groups.</measure>
  </secondary_outcome>
  <enrollment type="Actual">1496</enrollment>
  <condition>Hypercholesterolaemia</condition>
  <condition>Hyperlipidaemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0653, ezetimibe</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duration of Treatment: 3 months</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary hypercholesterolemia treated with any statin at any dose, for at least 3
             months with a ldl cholesterol above 115 mg/dl (esc 2003 recommendations).

        Exclusion Criteria:

          -  pregnant or breast feeding women

          -  Lipid-lowering agents including hmg-coa reductase inhibitors other than the current
             statin, fish oils, cholestyramin, niacin (&gt;200 mg/day) and fibrates taken within the 3
             months preceding visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <results_reference>
    <citation>Steg PG, Verdier JC, Carré F, Darne B, Ducardonnet A, Jullien G, Farnier M, Giral P, Haïat R; TWICE Investigators, France. A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE). Arch Cardiovasc Dis. 2008 Nov-Dec;101(11-12):723-35. doi: 10.1016/j.acvd.2008.10.008. Epub 2008 Nov 20.</citation>
    <PMID>19059567</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2006</study_first_submitted>
  <study_first_submitted_qc>May 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2006</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSRSynopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

